Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

Cristina Gasparetto, MD
Published: Monday, Jan 08, 2018



Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

In a phase lb study, the combination of selinexor and daratumumab was evaluated in patients with relapsed/refractory multiple myeloma who were previously exposed to proteasome inhibitors and immunomodulatory drugs.

This combination will move onto a phase II study with more patients, says Gasparetto, in order to effectively evaluate response, side effects, and efficacy.


Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

In a phase lb study, the combination of selinexor and daratumumab was evaluated in patients with relapsed/refractory multiple myeloma who were previously exposed to proteasome inhibitors and immunomodulatory drugs.

This combination will move onto a phase II study with more patients, says Gasparetto, in order to effectively evaluate response, side effects, and efficacy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x